HomeAI · summaries
Storia in 4 fonti
Biohaven strikes $795M deal for commercial partner in epilepsy
South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel platform, including its lead candidate opakalim.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a…
- ·
koreaherald.com
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the company said Wednesday. In a regulato
